[This corrects the article DOI: 10.3389/fmed.2022.850858.].
Keywords: COVID-19; SARS-CoV-2; disease-modifying anti-rheumatic drugs; humoral response; rheumatic musculoskeletal diseases; risk of infection; seroprevalence.
Copyright © 2022 Favalli, Gobbini, Bombaci, Maioli, Biggioggero, Pesce, Favalli, Martinovic, Fabbris, Marchisio, Bandera, Gori, Abrignani, Grifantini and Caporali.